Biotechnology, Pharmaceuticals, and Research by Summit Therapeutics
15.45
0.1101
0.72 %
Real-time price
15:01
USD
Daily range
15.09
15.50
15.50
Weekly range
14.39
15.65
15.65
SMMT climbs over 3% after technical oversold signals spark short-term buying
Summit Therapeutics (SMMT) advanced 3.21% as technical pressure eased following oversold signals and a volatile open that attracted short-term buyers. The rebound looks limited, with SMMT still ...
Summit Therapeutics enters clinical trial collaboration after stock ends session down 1.6%
Summit Therapeutics announced a new clinical trial partnership with the ECOG-ACRIN Cancer Research Group to study ivonescimab in first-line biliary tract cancer. Shares are down 1.6% on the day at ...
Summit Therapeutics stock rises nearly 6% as pivotal Phase II trial for ivonescimab begins in renal cell carcinoma
Summit Therapeutics (SMMT) jumped 5.68% after announcing the opening of clinical trial sites for a pivotal Phase II study of ivonescimab in advanced clear cell renal cell carcinoma. The rebound ...
Why is Summit Therapeutics stock down 8.2% today?
Summit Therapeutics (SMMT) slumped 8.23% as seller momentum persisted, even as anticipation builds for its upcoming Q3 2026 earnings release and a newly announced joint oncology initiative with ...
Why is Summit Therapeutics stock up 4.1% today?
Summit Therapeutics (SMMT) climbed 4.12% after the company confirmed receipt of a $2 billion equity investment from AstraZeneca to accelerate cancer drug development, marking a significant cash ...
SMMT climbs nearly 5% after AstraZeneca funds cancer drug development
Summit Therapeutics (SMMT) surged 4.7% after announcing a $2 billion equity investment from AstraZeneca to fund the development of its cancer therapy pipeline. The move is further supported by the ...
Summit Therapeutics falls around 4.5% as weak profitability and low growth drive investor caution
Summit Therapeutics (SMMT) slid 4.59% as weak profitability and low growth fundamentals reported by HC Wainwright & Co. accentuated investor hesitancy. The decline is currently limited by the ...
Summit Therapeutics stock falls over 5% as HARMONi trial update sparks selling pressure
Summit Therapeutics (SMMT) dropped 5.13% after updated Phase III HARMONi clinical trial data for ivonescimab showed consistent overall survival and safety outcomes in both Asian and Western ...
Summit Therapeutics shares drop about 4.5% after volatility follows bullish clinical data
Summit Therapeutics (SMMT) slid 4.56% as selling pressure followed an extended overbought rally, even as clinical trial data for its lung cancer candidate provided a strong fundamental backdrop. ...
Summit Therapeutics stock rises over 5% as new ivonescimab trial data boosts outlook
Summit Therapeutics (SMMT) surged 5.34% after highlighting new overall survival data from Akeso’s clinical trials involving ivonescimab, fueling investor optimism over its clinical progress. The ...
Summit Therapeutics stock rises nearly 4% as technical momentum and strong trend signals fuel buying
Summit Therapeutics (SMMT) advanced 3.95% today on the back of continued technical buying, as strong trend momentum and bullish signals drive the move. The rally is supported by SMMT trading above ...
What's behind Summit Therapeutics' latest stock pullback?
Summit Therapeutics (SMMT) fell 3.14% amid strong overbought signals and intraday selling pressure in the absence of new corporate catalysts. The move is contradicted by the stock’s position ...
What's behind Summit Therapeutics's latest 15.1% stock surge?
Summit Therapeutics (SMMT) surged 15.14% after positive clinical trial results and a favorable regulatory outlook for its lead asset ivonescimab drove strong demand. The move is supported by a ...
SMMT slides around 3.5% as technical weakness persists without new corporate news
Summit Therapeutics (SMMT) declined 3.56% today as technical factors led sentiment in the absence of any fresh corporate catalysts. The move is supported by the stock remaining below key moving ...
What's behind Summit Therapeutics's latest 4.7% stock surge?
Summit Therapeutics (SMMT) advanced 4.69% after an upside gap, with the move linked to short covering and a technical bounce. The rebound looks limited, as the stock continues to trade below all ...
SMMT slides around 6.5% as stock remains below key moving averages with weak momentum
Summit Therapeutics (SMMT) slid 6.46% under sharp selling pressure, as technical momentum signaled a continuation of its recent decline in the absence of a fresh catalyst. The downtrend is ...
Summit Therapeutics stock drops more than 6% after selloff triggered by weak price action below major moving averages
Summit Therapeutics (SMMT) fell 6.39% after a wave of selling triggered by ongoing technical weakness, even as the company expanded its drug Ivonescimab with key clinical and regulatory ...
Summit Therapeutics stock rises nearly 5% as strong technical momentum fuels gains
Summit Therapeutics (SMMT) surged 4.64% today amid strong technical momentum and sustained buying pressure, with the stock opening with an upside gap and pushing near session highs. The rally ...
SMMT climbs around 3.5% after technical strength boosts near-term sentiment
Summit Therapeutics (SMMT) advanced 3.44% as technical momentum and near-term buying strength drove renewed interest in the stock. The rebound is supported by the price moving above its 20-day and ...
Why is Summit Therapeutics stock down 4.8% today?
Summit Therapeutics (SMMT) fell 4.81% after the company released updated Phase III HARMONi overall survival data and set a PDUFA date for its ivonescimab program, accompanied by the launch of a ...
Summit Therapeutics shares fall around 9.5% as technical pressures and mixed trial updates weigh on sentiment
Summit Therapeutics (SMMT) dropped 9.48% after reporting a narrower-than-expected adjusted net loss for Q2 2026, with investors focusing on corporate developments and trial updates. The selloff is ...
